Mental disorders in current and former heavy ecstasy (MDMA) users

Addiction

Volumn 100, Issue 9, 2005, Pages 1310-1319

  Thomasius, R ^a   Petersen, K U ^a   Zapletalova, P ^a   Wartberg, L ^a   Zeichner, D ^a   Schmoldt, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cognitive disorders; DSM IV; Ecstasy; MDMA; Psychopathology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; FEMALE; HUMAN; MALE; MENTAL DISEASE; MOOD DISORDER; NEUROTOXICITY;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANXIETY DISORDERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MOOD DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 24344506132     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2005.01180.x     Document Type: Article

References (43)

1. Abt, K. (1987) Descriptive data analysis: a concept between confirmatory and exploratory data analysis. Methods of Information in Medicine, 26, 77-88.
2. American Psychiatric Association (APA) (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV-Tr). Washington, DC: APA.
3. Buchert, R., Thomasius, R., Nebeling, B., Petersen, K.-U., Obrocki, J., Jenicke, L. et al. (2003) Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. Journal of Nuclear Medicine, 44, 375-384.
4. Check, E. (2004) The ups and downs of ecstasy. Nature, 429, 126-128.
5. Cole, J. C. & Sumnall, H. R. (2003) Altered states: the clinical effects of ecstasy. Pharmacology and Therapeutics, 98, 35-58.
6. Cottler, L. B., Womack, S. B., Compton, W. M. & Ben-Abdallah, A. (2001) Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Human Psychopharmacology, 16, 599-606.
7. Daumann, J., Hensen, G., Thimm, B., Rezk, M., Till, B. & Gouzoulis-Mayfrank, E. (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berlin), 173, 398-404.
8. Daumann, J., Pelz, S., Becker, S., Tuchtenhagen, F. & Gouzoulis-Mayfrank, E. (2001) Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacology: Clinical and Experimental, 16, 627-633.
9. De Win, M. M., Reneman, L., Reitsma, J. B., den Heeten, G. J., Booij, J. & van den Brink, W. (2004) Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berlin), 173, 376-382.
10. Dughiero, G., Schifano, F. & Forza, G. (2001) Personality dimensions and psychopathological profiles of ecstasy users. Human Psychopharmacology, 16, 635-639.
11. European Monitoring Centre for Drugs & Drug Addiction (EMCDDA), eds (2004) Annual report 2004: the state of the drugs problem in the European Union and Norway. Available online at: http://annualreport.emcdda.eu.int/download/ ar2004-en.pdf [accessed 23 June 2005].
12. Flory, K. & Lynam, D. R. (2003) The relation between attention deficit hyper activity disorder and substance abuse: what role does conduct disorder play? Clinical Child and Family Psychology Review, 6, 1-16.
13. Gamma, A., Buck, A., Berthold, T. & Vollenweiden, F. X. (2001) No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a (H2150xx)-positron emission tomography study. Journal of Clinical Psychopharmacology, 21, 66-71.
14. Gerra, G., Zaimovic, A., Ferri, M., Zambelli, U., Timpano, M., Neri, E. et al. (2000) Long-lasting effects of (±)3,4-methylenedioxymetamphetamine (ecstasy) on serotonin system function in humans. Biological Psychiatry, 47, 127-136.
15. Gerra, G., Zaimovic, A., Giucastro, G., Maestri, D., Monica, C. & Sartori, R. (1998) Serotonergic function after 3,4-methylenedioxymethamphetamine ('ecstasy') in humans. International Journal of Clinical Psychopharmacology, 13, 1-9.
16. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E. & Colado, M. I. (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacology Reviews, 55, 463-508.
17. Hanson, K. L. & Luciana, M. (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychological Medicine, 34, 229-246.
18. Khantzian, E. J. (1997) The self-medication hypothesis of substance abuse disorders: reconsideration and recent applications. Harvard Review of Psychiatry, 4, 231-244.
19. Latimer, W. W., Stone, A. L., Voight, A., Winters, K. C. & August, G. J. (2002) Gender differences in psychiatric comorbidity among adolescents with substance use disorders. Experimental and Clinical Psychopharmacology, 10, 310-315.
20. Lehrl, S. (1995) Mehrfachwahl-Wortschatz-Intelligenztest, (MWT-B) (Multiple Choice Verbal Intelligence Test), 3rd edn. Balingen: Medizinische Verlagsgesellschaft mbH.
21. Lieb, R., Schuetz, C. G., Pfister, H., von Sydow, K. & Wittchen, H. (2002) Mental disorders in ecstasy users; a prospective-longitudinal investigation. Drug and Alcohol Dependence, 68, 195-207.
22. McCardle, K., Luebbers, S., Carter, J. D., Croft, R. J. & Stough, C. (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berlin), 173, 434-439.
23. McGuire, P. K., Cope, H. & Fahy, T. A. (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('ecstasy'). British Journal of Psychiatry, 165, 391-395.
24. MacInnes, N., Handley, S. L. & Harding, G. F. A. (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Journal of Psychopharmacology, 15, 181-186.
25. Morgan, M. J. (2000) Ecstasy (MDMA): a review of is possible persistent psychological effects. Psychopharmacology, 152, 230-248.
26. Morgan, M. J., McFie, L., Fleetwood, L. H. & Robinson, J. A. (2002) Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology, 159, 294-303.
27. Nichols, D. E. (1986) Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. Journal of Psychoactive Drugs, 18, 305-313.
28. O'Regan, M. C. & Clow, A. (2004) Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology (Berlin), 173, 446-451.
29. Parrott, A. C. (2001) Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experiment, 16, 557-577.
30. Parrott, A. C. (2004) MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology, 50, 329-335.
31. Parrott, A. C., Sisk, E. & Turner, J. J. D. (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug and Alcohol Dependence, 60, 105-110.
32. Ricaurte, G., Bryan, G., Strauss, L., Seiden, L. & Schuster, C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science, 229, 986-988.
33. Rowland, A. S., Lesesne, C. A. & Abramowitz, A. J. (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Mental Retardation and Developmental Disabilities Research Reviews, 8, 162-170.
34. Schifano, F., Di Furia, L., Forza, G., Minicuci, N. & Bricolo, R. (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug and Alcohol Dependence, 52, 85-90.
35. Schuster, P., Lieb, R., Lamertz, C. & Wittchen, H. U. (1998) Is the use of ecstasy and hallucinogens increasing? European Addiction Research, 4, 75-82.
36. Soar, K., Parrott, A. C. & Fox, H. C. (2004) Persistent neuropsychological problems after 7 years of abstinence from recreational ecstasy (MDMA): a case study. Psychological Reports, 95, 192-196.
37. Soar, K., Turner, J. J. D. & Parrott, A. C. (2001) Psychiatric disorders in ecstasy (MDMA) users; a literature review focusing on personal predisposition and drug history. Human Psychopharmacology: Clinical and Experimental, 16, 641-645.
38. Thomasius, R., Petersen, K.-U., Buchert, R., Andresen, B., Zapletalova, P., Wartberg, L. et al. (2003) Mood, cognition, and serotonin transporter availibility in current and former ecstasy (MDMA) users. Psychopharmacology, 167, 85-96.
39. Vecellio, M., Schopper, C. & Modestin, J. (2003) Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: possible evidence for toxicity-vulnerability predictors and implications for preventative and clinical care. Journal of Psychopharmacology, 17, 342-345.
40. Verheyden, S. L., Maidment, R. & Curran, H. V. (2003) Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. Journal of Psychopharmacology, 17, 371-378.
41. Von Sydow, K., Lieb, R., Pfister, H., Hofler, M. & Wittchen, H. U. (2002) Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug and Alcohol Dependence, 66, 147-159.
42. Whitaker-Azmitia, P. M. & Aronsan, T. A. (2001) 'Ecstasy' (MDMA)-induced panic. American Journal of Psychiatry, 146, 119.
43. Wittchen, H.-U., Wunderlich, U., Gruschwitz, S., S. & Zaudig, M. (1997) Strukturiertes Klinisches Interview Für DSM-IV (SKID), Achse I: Psychische Störungen, Interviewheft [Structured Clinical Interview for DSM-IV (SKID), Axis I: Psychological Disorders, Interview Guide]. Göttingen: Hogrefe.